|
# # # # The treatment of Parkinson’s has long been defined by medications that increase the level of a chemical called dopamine in the brain. The cells that produce dopamine are progressively lost in this condition. To date, dopamine-replacement therapies have largely been based on orally administered pills that result in fluctuating levels of dopamine across the day. But now regulators have approved a new treatment that provides continuous levels of dopamine. It is called Produodopa. In today’s post, we will look at what is dopamine, why the treatments supplementing dopamine fluctuate across the day, and how Produodopa may be able to help with this. # # # # |
Source: Bwcharity
One neurologist described it to me as the ‘Deep brain stimulation killer’.
I’m not so sure about that.
Others have suggested that it has the potential to be a revolutionary shift for the future treating Parkinson’s.
Again, I wouldn’t go that far, but it could be a very important step forward in better management of motor symptoms in advanced Parkinson’s.
What are we talking about here?
It is called Produodopa, and it is a new system of continuous delivery of levodopa that has been developed by the pharmaceutical company AbbVie.
Produodopa was launched in the European Union in January 2024 (Click here to read more about this), and was approved for clinical use in England by the National Institute for Health and Care Excellence (NICE) on the October 26th 2023 (Click here to read more). It is still awaiting approval in the USA.
And what exactly is Produodopa?
The Science of Parkinson's 